News

Some Fallopian Tube Lesions Represent Ovarian Cancer Metast...

Some Fallopian Tube Lesions Represent Ovarian Cancer Metastases, Not Precursor Lesions

December 21, 2016

(Dec. 21, 2016) Research published recently in Cancer Discovery suggests that cells in the fallopian tube previously thought to be precursors to high grade serous ovarian cancer may sometimes be cells that have metastasized and implanted into the fallopian tube. The research was conducted by a team at the University of Chicago under the guidance … Continued

Research

Rucaparib FDA Approved for Advanced Ovarian Cancer with BRC...

Rucaparib FDA Approved for Advanced Ovarian Cancer with BRCA Mutations

December 19, 2016

(Dec. 19, 2016) The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as … Continued

Research

Federal Funding for Ovarian Cancer: 2016 Highlights

Federal Funding for Ovarian Cancer: 2016 Highlights

December 19, 2016

As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level. In 2016, with the help of committed Advocate Leaders, Grassroots Advocates, Research Advocates and action alert supporters, OCRFA was able to: We’ve made great strides in ensuring that ovarian … Continued

Advocacy

Five Important Discoveries from OCRFA-Funded Researchers in...

Five Important Discoveries from OCRFA-Funded Researchers in 2016

December 15, 2016

OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and prevent the disease, and discover better treatments. In 2016, our grantees made significant advances in the fight against ovarian cancer, including: Progress is being made … Continued

OCRA News

Turn Up the Heat Tickets Now Available

Turn Up the Heat Tickets Now Available

December 15, 2016

Tickets are now available for the 2017 Turn Up the Heat! Gala in Washington DC. Turn Up the Heat features food from the top female chefs in DC and the surrounding area! Join us on February 22nd for a night full of delicious food and great company. Get your tickets at www.turnuptheheatgala.org

Events

Kolker Fellowship Deadline Approaching

Kolker Fellowship Deadline Approaching

December 14, 2016

The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker. At the time Ann was diagnosed with ovarian cancer in 1996, she was already a political powerhouse, having early involvement with organizations like the National Women’s Political Caucus and Emily’s List. We are now accepting applications for the Fall 2017 Fellowship.

Advocacy

FDA Approves Avastin for Platinum-Sensitive Recurrent Ovari...

FDA Approves Avastin for Platinum-Sensitive Recurrent Ovarian Cancer

December 9, 2016

(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone. The approval is based on two large Phase III … Continued

Research

Managing Recurrence: What You Need to Know (Webinar Available)

Managing Recurrence: What You Need to Know (Webinar Available)

November 30, 2016

Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing recurrent ovarian cancer, discussing the goals of treatment during recurrence, typical courses of treatment, and advice on how to approach making decisions about treatment during … Continued

Information

OCRFA Welcomes New Scientific Advisory Committee Members

OCRFA Welcomes New Scientific Advisory Committee Members

November 10, 2016

OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. Ronald Alvarez, MD, MBA, of Vanderbilt University Medical Center, Deborah Armstrong, MD, of Johns Hopkins School of Medicine, Robert Coleman, MD, of M.D. Anderson Cancer … Continued

OCRA News

OCRFA Funded Research Identifies Protein Group Responsible ...

OCRFA Funded Research Identifies Protein Group Responsible For Senescence’s Negative Side Effects

November 3, 2016

(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side … Continued

OCRA News

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tu...

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tumor Immunity

October 31, 2016

(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor growth, can sometimes be effectively treated with anti-estrogen therapy, such as tamoxifen. What is less understood, and currently being studied at the Wistar Institute, is … Continued

OCRA News

OCRFA Launches New Website

OCRFA Launches New Website

October 14, 2016

We’re excited to announce that OCRFA’s new and refreshed website is live. The new site is reflective of the merger of Ovarian Cancer Research Fund and the Ovarian Cancer National Alliance to become Ovarian Cancer Research Alliance or OCRFA, the largest and oldest non-profit organization dedicated to advancing cancer research, while supporting women and their … Continued

OCRA News